體外診斷板塊領漲A股 邁克生物(300463.SZ)等多股漲停
格隆匯4月20日丨科創板的碩世生物和熱景生物漲超11%,新開源、科華生物、華大基因、透景生命、邁克生物、達安基因漲停,基蛋生物、普門科技、凱普生物、潤達醫療和東方生物等均大漲。有報告顯示,中國生化診斷市場,上市企業集中,競爭最為激烈。其中中生北控和科華生物是上市最久的體外診斷企業。中國本土有超過1000家體外診斷企業,但是邁克生物、萬孚生物、安圖生物、美康生物、科華生物等公司市場份額仍能實現穩定增長。碩世生物4月19日晚間公告稱,公司產品新型冠狀病毒2019-nCoV核酸檢測試劑盒(熒光PCR法)已取得醫療器械註冊證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.